NCT06389552招募中不适用
A Long-term Follow-up Study of FOLFIRINOX Regimen as Adjuvant Therapy in Pancreatic Cancer Patients After Curative Surgery: Multi-center, Prospective
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Disease-free survival
研究概览
简要总结
This study is designed to evaluate the safety and efficacy of adjuvant FOLFIRINOX regimen in pancreatic cancer patients after curative surgery.
详细描述
This study is multi-center, prospective, long-term follow-up observational study.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age over 19 at the time of obtaining the informed consent form
- •Planning to FOLFIRINOX as adjuvant therapy after pancreatic cancer surgery
- •ECOG 0 or 1
- •Scheduled to RO or R1 resection
- •Organ function capable of chemotherapy
排除标准
- •FOLFIRINOX contraindications among the drug approval requirements
- •Palliative Therapy
- •Experienced toxic reactions or Hypersensitivity reactions of FOLFIRINOX
结局指标
主要结局
Disease-free survival
时间窗: Day 1 to Week 88
Duration of survival before pancreatic cancer recurrence or death
次要结局
- Overall survival(Day 1 to Week 88)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Neoadjuvant FOLFIRINOX Regimen in Patients With Non-metastatic Pancrease CancerPancreas CancerLocalized Pancreas CancerNon-metastatic Pancreas CancerNCT01771146Baylor Research Institute30
进行中（未招募）
2 期
MFOLFIRINOX with or Without Stereotactic Body Radiotherapy in Locally Advanced Pancreatic AdenocarcinomaPancreatic AdenocarcinomaPancreatic Cancer Non-resectableNCT04986930Asan Medical Center92
进行中（未招募）
2 期
FOLFIRINOX + Elraglusib + Losartan In Pancreatic CancerPancreatic AdenocarcinomaPancreatic Adenocarcinoma MetastaticNCT05077800Colin D. Weekes, M.D., PhD70
已完成
2 期
FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic CancerMetastatic Pancreatic AdenocarcinomaNCT01896869Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins83
已完成
2 期
Efficacy and Safety of mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients.Pancreatic Cancer ResectableNCT04224402Yuhong Li80